Open AccessIntravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy
Author(s) -
Vincenzo Serretta,
Francesco Sommatino,
Cristina Scalici Gesolfo,
Vito Franco,
Giuseppe Cicero,
Rosalinda Allegro
Publication year - 2015
Publication title -
urology annals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.355
H-Index - 20
eISSN - 0974-7834
pISSN - 0974-7796
DOI - 10.4103/0974-7796.148582
Subject(s) - medicine , bladder cancer , context (archaeology) , proportional hazards model , cystoscopy , urology , retrospective cohort study , chemotherapy , multivariate analysis , surgery , cancer , urinary system , paleontology , biology
The therapeutic strategy in intermediate risk (IR) non-muscle invasive bladder cancer (NMIBC) recurring after intravesical therapy (IT) is not well defined. Most patients are usually retreated by Bacillus Calmette-Guerin (BCG).